Compared to traditional PCa biomarkers such as prostate-specific antigen (PSA) and androgen receptor (AR) variants, BAIAP2L2 may offer complementary value, particularly in cases where PSA levels lack specificity or AR variants contribute to therapy resistance. Here, AR is linked to posterior cortical atrophy.